News and Announcements
Trends & Developments in Life Sciences: Insights from Top Experts in Investment & Innovation
- Published March 28, 2023 5:18AM UTC
- Publisher Jade Miguel
- Categories Capital Insights
Covid-19 has highlighted the importance of health and spurred remarkable advancements in the Life Sciences & Genomics sector.
Join Leslie Chong, Hsien Hui Tong, Victoria Gordon, and Kelly Constable as they discuss the impact of Covid-19 on Life Sciences investment, current trends, and opportunities for the sector in the next 1-2 years.
Moderated by Glen Cross, Director of Horizon 3 Biotech Fund, this video is a must-watch for investors and innovators in the Life Sciences space.
#VentureCapital #Innovation #WholesaleInvestor
Capital Insights
Capital Flight or Policy Oversight? The $180M Seismic Shift Threatening Australian Innovation
A formal Senate submission by Wholesale Investor / CapitalHQ details the alarming real-world reactions of 260 founders and investors to proposed federal tax changes. With 91% of sophisticated investors scaling back local allocations and over $180M already paused or redirected offshore, the report warns of a structural funding crisis threatening the future of Australian deep tech, private equity, and startup innovation.
The Yield Illusion: Inside RAM’s Strategy to Withstand the Credit Shakeout
As interest rates reprice in 2026, the rush into private credit has created a dangerous trap for yield-hungry investors. Real Asset Management Group CEO Scott Kelly exposes the “yield illusion” dominating the market and explains why an origination-led, low-arrears mortgage strategy is the ultimate defense against an impending credit shakeout.
Office sector ‘unloved’ no more: Acure’s $80m Brisbane bet
While institutional investors remain wary of the office sector, Acure Asset Management is doubling down. Founder Angelo Del Borrello explains the “unloved” asset strategy behind his latest $80 million Brisbane acquisition and why the 2032 Olympics are creating a unique arbitrage opportunity for private syndicates.
Backed By Leading Investment Groups and Family Offices
